📰 Fredd Lublin News
Fredd Lublin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Fredd Lublin. Real-time updates on events, politics, business and more.
January 27, 2023
Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say thats both a blessing and problem.
November 17, 2022
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting
November 17, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
November 17, 2022
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential 17.11.2022 / 12:30 CET/CEST The issuer is solely responsible for th...
November 10, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences ...
November 10, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
November 10, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely